COMMUNIQUÉS West-GlobeNewswire

Philips receives FDA 510(k) clearance for next-generation reusable SpO₂ clip sensor
21/07/2026
July 21, 2026 New sensor advances pulse oximetry reliability for diverse patient populations through innovation and rigorous validation. Cambridge, MASS – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health [...]
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
21/07/2026
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing [...]
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
21/07/2026
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Lonza and Engitix Announce License Agreement to Advance Targeted ADC Development
21/07/2026
Lonza grants Engitix target-specific license for GlycoConnect ® , HydraSpace ® and SYNtecan E™ linker-payload technologies for ADC development Collaboration enables innovative treatments by combining Lonza’s validated [...]
Standard Dental Labs Announces Acquisition Capital Strategy to Support Next Phase of Florida Expansion
21/07/2026
ORLANDO, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (OTCQB: TUTH) ("SDL" or the "Company"), a consolidator of dental laboratories throughout Florida, today announced that its Board of Directors [...]
Exagen to Announce Second Quarter Financial Results on August 4, 2026
21/07/2026
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market [...]
Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market
21/07/2026
Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: [...]
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
21/07/2026
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today [...]
NeuroSigma Announces U.S. Commercial Launch of Second-Generation Monarch® eTNS System for Pediatric ADHD
21/07/2026
U.S. Commercial launch of Gen 2 Monarch System commencing today, July 21, 2026 Gen 2 Monarch device provides an enhanced patient experience while delivering clinically proven therapeutic stimulation of the trigeminal [...]
AssistRx and Medisafe Unite to Power Smarter, More Connected Patient Engagement
21/07/2026
Partnership delivers the real-time status updates and mobile-first engagement today's patients expect from therapy initiation through adherence ORLANDO, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- AssistRx , the advanced [...]
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
21/07/2026
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell disease [...]
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
21/07/2026
TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
21/07/2026
AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients Study underway with first [...]
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
21/07/2026
750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk ACTON, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX [...]
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
21/07/2026
Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- [...]
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
21/07/2026
MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the [...]
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
21/07/2026
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and [...]
Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange
21/07/2026
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today [...]
OKYO Pharma Announces Purchase of Shares by Chairman
21/07/2026
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]

Pages